keyword
MENU ▼
Read by QxMD icon Read
search

areata alopecia

keyword
https://www.readbyqxmd.com/read/28646393/the-changing-landscape-of-alopecia-areata-the-therapeutic-paradigm
#1
REVIEW
Yael Renert-Yuval, Emma Guttman-Yassky
Alopecia areata (AA), a prevalent inflammatory cause of hair loss, lacks FDA-approved therapeutics for extensive cases, which are associated with very poor rates of spontaneous hair regrowth and major psychological distress. Current treatments for severe cases include broad immune-suppressants, which are associated with significant adverse effects, precluding long-term use, with rapid hair loss following treatment termination. As a result of the extent of the disease in severe cases, topical contact sensitizers and intralesional treatments are of limited use...
June 23, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28646392/the-changing-landscape-of-alopecia-areata-the-translational-landscape
#2
REVIEW
Etienne C E Wang, Angela M Christiano
Recent genetic and preclinical studies have increased our understanding of the immunopathogenesis of alopecia areata (AA). This has allowed expedited development of targeted therapies for the treatment of AA, and a paradigm shift in our approach and understanding of autoimmunity and the hair follicle. The synergy between preclinical studies, animal models, and translational studies has led to unprecedented advances in the treatment options for AA, ultimately benefiting patients who have had little recourse...
June 23, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28646391/the-changing-landscape-of-alopecia-areata-an-introduction
#3
REVIEW
George Han
Alopecia areata is an extremely common autoimmune condition affecting hair. Severe forms of alopecia areata exist, with existing treatments consisting of systemic immunosuppressants with numerous side effects. Recently, breakthroughs have been made in both understanding the pathogenesis of alopecia areata and the treatment thereof, which hold the promise of being able to target severe cases of alopecia areata with more efficacy and better tolerability. This article serves as an introduction to review papers from two of the leading researchers in the field of alopecia areata...
June 23, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28641742/the-good-and-bad-news-about-new-drugs-for-treating-alopecia-areata
#4
D Morgado-Carrasco, E Rodríguez-Lobato, J Riera-Monroig, J Ferrando
No abstract text is available yet for this article.
June 19, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28638587/association-between-helicobacter-pylori-infection-and-alopecia-areata-a-study-in-iranian-population
#5
Elham Behrangi, Parvin Mansouri, Shahram Agah, Nasser Ebrahimi Daryani, Marjan Mokhtare, Zahra Azizi, Mona Ramezani Ghamsari, Masoumeh Rohani Nasab, Zahra Azizian
BACKGROUND Alopecia areata is an immune mediated inflammatory hair loss, which occurs in all ethnic and age groups, and both sexes. However no significant etiology has been known for this disease. Helicobacter pylori (H. pylori) , is an organism colonized in gastric mucosa. This bacterium has been associated with certain extra-digestive dermatological conditions. The causal relationship between alopecia areata and H. pylori infection has been discussed in literature. Therefore, we conducted this study to evaluate the prevalence of H...
April 2017: Middle East Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28635319/a-case-of-topical-ruxolitinib-treatment-failure-in-alopecia-areata
#6
Maya Deeb, Renée A Beach
Alopecia areata (AA) is an autoimmune-mediated, nonscarring form of hair loss. Despite its prevalence, current management options are limited, especially when the disease has progressed to alopecia totalis (AT) or alopecia universalis (AU). Recent evidence that janus kinase (JAK) signaling contributes to AA pathogenesis prompted the investigation of JAK inhibitors such as tofacitinib and ruxolitinib as possible oral treatments. However, the potential for significant adverse effects with systemic JAK inhibition makes local administration a more attractive option...
June 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28632888/excellent-response-to-tofacitinib-in-a-patient-with-alopecia-universalis
#7
Funda Erduran, Esra Adışen, Ahmet Burhan Aksakal
EAlopecia universalis (AU) is generally considered a variant of alopecia areata (AA), in which the treatment options seldom provide satisfactory results. However, successful treatment of several cases of AA and its variants with oral Janus kinase (JAK) inhibitors have been reported recently. Here we report a 23-year-old female patient with AU successfully treated with tofacitinib, a selective JAK-3 inhibitor. The initial tofacitinib dose was 5 mg twice daily. After 2 months of treatment, partial hair regrowth was seen on the scalp and eyebrows...
June 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/28627278/methotrexate-for-the-treatment-of-pediatric-alopecia-areata
#8
Erin T Landis, Rita O Pichardo-Geisinger
Alopecia areata is a form of nonscarring hair loss which occurs in pediatric and adult patients, with presentation varying from round or ovoid patches of alopecia to alopecia totalis or universalis. While frustrating for patients, it can also be frustrating for clinicians to treat, as there is no definitive treatment. Dermatologists are very familiar with the use of methotrexate for psoriasis and other inflammatory skin diseases, and this medication is generally well tolerated in children. This study present a case series reviewing the efficacy of methotrexate in our pediatric patients with alopecia areata, making use of a retrospective chart review design from 2011-2016...
June 19, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28619558/systematic-review-and-quality-analysis-of-studies-on-the-efficacy-of-topical-diphenylcyclopropenone-treatment-for-alopecia-areata
#9
Yong Hyun Jang, Han Jin Jung, Sun Young Moon, Weon Ju Lee, Seok-Jong Lee, Won Kee Lee, Do Won Kim
No abstract text is available yet for this article.
July 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28619556/topical-janus-kinase-inhibitors-for-the-treatment-of-pediatric-alopecia-areata
#10
Cheryl B Bayart, Katherine L DeNiro, Lars Brichta, Brittany G Craiglow, Robert Sidbury
No abstract text is available yet for this article.
July 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28616235/exacerbation-of-alopecia-areata-a-possible-complication-of-sodium-tetradecyl-sulphate-foam-sclerotherapy-treatment-for-varicose-veins
#11
Mark S Whiteley, Victoria C Smith
A 40-year-old woman with a history of alopecia areata related to stress or hormonal changes was treated for bilateral primary symptomatic varicose veins (CEAP clinical score C2S) of pelvic origin, using a staged procedure. Her first procedure entailed pelvic vein embolisation of three pelvic veins using 14 coils and including foam sclerotherapy of the tributaries, using 3% sodium tetradecyl sulphate. Following this procedure, she had an exacerbation of alopecia areata with some moderate shedding of hair. Subsequently, she underwent endovenous laser ablation under local anaesthetic without incident...
2017: SAGE open medical case reports
https://www.readbyqxmd.com/read/28598005/higher-concentrations-of-dithranol-appear-to-induce-hair-growth-even-in-severe-alopecia-areata
#12
M R Ngwanya, N A Gray, F Gumedze, A Ndyenga, N P Khumalo
Alopecia areata (AA) is the commonest autoimmune cause of non-scarring alopecia. Topical treatments including corticosteroids and irritants maybe beneficial. Studies report variable hair regrowth with dithranol (anthralin) but all used low concentrations (0.1-1.25%) and inconsistent measurements of AA severity. We report retrospective data (2005-2014) of 102 patients who had failed ultra-potent topical steroids and were referred to a specialist hair clinic for treatment with dithranol up to 3%. The severity of alopecia areata tool was used and participants graded as mild (<25%), moderate (>25 to 75%), and severe (>75%) hair loss...
June 9, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28587354/th1-th2-pb-balance-and-cd200-expression-of-patients-with-active-severe-alopecia-areata
#13
Xinhua Ma, Shisheng Chen, Wanwan Jin, Yu Gao
Th1/Th2 peripheral blood balance and CD200 expression in patients with severe alopecia areata (SAA) in the active stage were investigated. Fifty patients with active SAA, 50 patients with stable SAA and 50 healthy controls were continuously selected and expression of Th1/Th2 of peripheral T lymphocytes, and peripheral B lymphocytes was detected by flow cytometry; RT-PCR was used to detect the expression of the PBMC CD200 mRNA and the expression of CD200 in hair follicles of alopecia area was detected by immunohistochemically staining; ELISA was used to detect expression levels of serum LFN-γ and serum interleukin (IL)-10...
June 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28581240/immune-checkpoint-inhibitor-associated-alopecia-areata
#14
T Ito
No abstract text is available yet for this article.
June 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28566900/low-dose-systemic-methotrexate-therapy-for-recalcitrant-alopecia-areata
#15
Seul-Ki Lim, Cho-Ah Lim, In Sun Kwon, Myung Im, Young-Joon Seo, Chang-Deok Kim, Jeung-Hoon Lee, Young Lee
BACKGROUND: Alopecia areata (AA) is an autoimmune skin disease difficult to manage and treat. The pathogenesis of AA features a T-cell-associated autoimmune process, and systemic immunosuppressive therapy is prescribed widely for AA. OBJECTIVE: To evaluate the efficacy and tolerance of systemic low-dose methotrexate (LD-MTX) therapy in treatment of recalcitrant AA multiplex. METHODS: In a retrospective, non-controlled study, we evaluated 29 patients with recalcitrant AA treated with LD-MTX and assessed the therapeutic response according to severity of disease, disease duration, cumulative dose of MTX, and drug safety...
June 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28555441/alopecia-areata-of-the-beard-a-review-of-the-literature
#16
REVIEW
Jessica Cervantes, Raymond M Fertig, Austin Maddy, Antonella Tosti
Alopecia areata (AA) is a T-cell mediated autoimmune disorder in which inflammatory cells attack the hair follicle, resulting in round, well-circumscribed patches of noncicatricial hair loss in normal appearing skin. AA affecting the beard area is well known and is referred to as AA of the beard (BAA) or AA barbae when involvement is limited exclusively to the beard. BAA has been documented in a select number of studies. We review the literature and discuss the clinical features, epidemiology, diagnosis, and treatment of BAA...
May 29, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28554321/phosphodiesterase-4-inhibitors-in-immune-mediated-diseases-mode-of-action-clinical-applications-current-and-future-perspectives
#17
Lazaros I Sakkas, Athanasios Mavropoulos, Dimitrios P Bogdanos
Phosphodiesterase (PDE) 4 is a superfamily of enzymes that catalyze the hydrolysis of cyclic adenosine 3',5'-monophosphate (cAMP), an intracellular second messenger and regulator of a wide array of genes and proteins. Increased levels of intracellular cAMP lead to activation of genes but also to inhibition of nuclear factor-kappa B, involved in pro-inflammatory responses. By increasing cAMP levels, PDE4 inhibitors, such as apremilast, reduced production of pro-inflammatory TNFα, IFNγ, and IL-17 and increased production of anti-inflammatory IL-10 in lipopolysaccharide-stimulated peripheral blood mononuclear cells, and in patients with psoriatic arthritis (PsA)...
May 29, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28551734/alopecia-areata-an-update-on-treatment-options-for-children
#18
REVIEW
Lauren Peloquin, Leslie Castelo-Soccio
Pediatric alopecia areata is a spectrum of autoimmune non-scarring alopecia in which some patients lose small patches of hair from their scalp but others lose more or all of the hair from the scalp and body, including eyebrows and eyelashes. Few studies have looked at therapies for this disorder in children, so much of the data are derived from adult literature and describe off-label use of medication. Generally, topical therapies consisting of topical steroids and topical irritating compounds/contact sensitizers are used...
May 27, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28546083/mechanisms-of-tolerance-and-potential-therapeutic-interventions-in-alopecia-areata
#19
REVIEW
Gabriel Skogberg, Sonya Jackson, Annika Åstrand
This review aims to address the mechanisms of compromised immune tolerance contributing to the development and maintenance of Alopecia Areata (AA). Our goal is to also highlight future treatment opportunities and therapeutics that will safely and efficiently restore hair growth and maintain patients in remission. AA is a presumptive autoimmune disorder that coincides and genetically clusters to several other autoimmune diseases. In this review, we pay attention to the learnings from the mechanistic research and drug development in these other autoimmune conditions...
May 22, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28530053/-alopecia-areata
#20
REVIEW
Yaron Zafrir, Sharon Baum, Shoshi Greenberger, Anna Lyakhovitsky, Aviv Barzilai
Alopecia areata (AA) is an organ specific autoimmune disease. Similar to other autoimmune diseases, its pathogenesis is believed to be an interaction of genetic, environmental and immune factors. Studies have shown that autoreactive lymphocytes affect anagen hair follicles leading to subsequent shedding of hairs and alopecia. Clinically, the disease is characterized by sudden nonscarring hair loss that usually involves the scalp, but may also affect the face and other body areas, and indeed the entire body hair...
October 2016: Harefuah
keyword
keyword
82787
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"